Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Other Operating Expenses (2016 - 2025)

Fennec Pharmaceuticals filings provide 5 years of Other Operating Expenses readings, the most recent being $7.9 million for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 70.6% to $7.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $22.4 million, a 3.57% increase, with the full-year FY2025 number at $22.4 million, up 3.56% from a year prior.
  • Other Operating Expenses hit $7.9 million in Q4 2025 for Fennec Pharmaceuticals, up from $5.9 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $7.9 million in Q4 2025 to a low of -$10.0 million in Q2 2022.
  • Median Other Operating Expenses over the past 4 years was $4.6 million (2023), compared with a mean of $3.6 million.
  • Biggest five-year swings in Other Operating Expenses: skyrocketed 124.84% in 2023 and later tumbled 42.35% in 2025.
  • Fennec Pharmaceuticals' Other Operating Expenses stood at $2.8 million in 2022, then surged by 63.48% to $4.6 million in 2023, then grew by 1.32% to $4.6 million in 2024, then surged by 70.6% to $7.9 million in 2025.
  • The last three reported values for Other Operating Expenses were $7.9 million (Q4 2025), $5.9 million (Q3 2025), and $5.3 million (Q2 2025) per Business Quant data.